The desire for patients to have a personalized approach to care is repeated throughout the ad, which was produced by Avalere ...

Chemotherapy is one of the most popular ways to treat breast cancer. Even though it has proven to be effective, it also has downsides, such as a higher risk of side effects, as it doesn't only ...

Joincare Pharmaceutical Group Industry Co. Ltd.-0.93% ¥19.22B Tianjin Pharmaceutical Da Ren Tang Group Corp. Ltd. A 0.00% ¥25.86B Kangmei Pharmaceutical Co. Ltd. A 2.08% ¥27.1B Hainan Haiyao Co ...

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, SKYTROFA ®, and YORVIPATH ® are trademarks owned by the Ascendis Pharma group.

COPENHAGEN, Denmark, May 01, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2025, and provided a business update.

COPENHAGEN, Denmark, May 01, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2025, and provided a business update.

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. Discussing two decades of Mad Money, Jim Cramer took a moment ...

When President Trump signed an executive order this month to try to reduce drug prices, the pharmaceutical industry scored a big win. Within 90 days, the order said, Trump’s staff should put ...

Silo Pharma’s SP-26 met all preclinical endpoints and aims to qualify for the FDA’s streamlined 505(b)(2) pathway. Today's manic market swings are creating the perfect setup for Matt’s next ...

When it comes to moms, there’s no one better than yours, which is why it's extra important to recognize her — or any other special woman in your life — this Mother's Day. After all, moms ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug ...